This Swiss Startup's Tiny Device Could Transform Prenatal Surgery

Jan de Vries · 2026-08-31

So, here's something that makes you think. A startup in Zurich just landed a big vote of confidence from investors, and it's all about making one of the most delicate surgeries in the world a little bit safer. KOVE Medical, a MedTech company that spun out of research at the University of Zurich, has secured $1.8 million in funding. That's right from a group of angel investors who see the potential. This fresh capital is the fuel the company needs to push forward into First-in-Human studies for a truly innovative device. CEO and co-founder Yannick Devaud put it perfectly, saying, “Thanks to the team and our strong Angel investors team. Let's go tackle health issues at the beginning of life!” ### The Big Problem KOVE Is Solving Let's break this down. KOVE is focused on a procedure called fetoscopy. It's a minimally invasive surgery where doctors operate on babies *before* they're born. It can treat serious conditions like spina bifida or twin-to-twin transfusion syndrome, which is incredible. But there's a catch. To perform the surgery, instruments have to pass through the uterine wall and the amniotic sac. That puncture creates a tiny opening. That opening can weaken the fetal membrane, allowing amniotic fluid to leak. Sometimes, this leads to the membrane rupturing too early, and that can cause preterm birth. It's a major limitation that holds back what these life-changing procedures can do. ### A Simple, Smart Solution KOVE's idea is elegantly simple. They're developing a small, implantable device designed to close that puncture site *from the inside* after the surgery is done. Think of it like a high-tech sealant for the amniotic membrane. Here's what makes it clever: - It's designed to work with the entry ports surgeons are already using, so no extra puncture is needed. - The company says it can be positioned in less than five minutes. - The goal is to stabilize the membrane right at the weak spot, potentially preventing leaks and reducing the risk of premature rupture. It’s one of those ideas where you wonder, why hasn't this been done before? The longer-term vision is huge: giving surgeons a reliable way to close up after prenatal procedures could open the door to more complex interventions and help more families. ### A Wave of European MedTech Investment This funding isn't happening in a vacuum. 2026 is shaping up to be a strong year for medical device innovation across Europe. Just look at some of the other recent deals: - FineHeart, a French cardiac-device developer, raised a massive $88 million. - Ireland's Neurent Medical brought in $66 million for minimally invasive treatments. - Xeltis, a Dutch-US vascular implant company, secured $21.6 million. - SamanTree Medical in Belgium got $21.1 million for surgical imaging. - Even in Switzerland, Lausanne-based Xsensio raised $6.3 million for wearable biochemical sensors. When you add it all up, we're talking about roughly $204 million in disclosed funding flowing into European MedTech startups this year. That's a serious signal of confidence in the sector's future. KOVE's statement really captures the moment: “This is a crucial step forward for our company, and we are incredibly grateful for the strong support and trust from our syndicate of visionary angel investors.” Founded back in 2020 by Yannick Devaud and Kurt Ruffieux, KOVE Medical is now on a clear path. They've pinpointed a critical, unaddressed complication in fetal surgery. With this new funding, they're charging ahead to turn their solution into a reality. It's a reminder that sometimes, the biggest leaps in medicine come from solving a single, specific problem with a smart piece of engineering.